GO2 - Alternative chemotherapy for frail or elderly patients with advanced gastric or oesophageal cancer: a randomised controlled trial
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 03 Nov 2017
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms GO2
- 04 Aug 2017 Planned End Date changed from 31 Oct 2016 to 31 Dec 2018.
- 17 Dec 2015 Accrual to date is 48% as per the United Kingdom Clinical Research Network record.
- 04 Nov 2015 Accrual to date is 44% as per the United Kingdom Clinical Research Network record.